REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
28/04/2025
Voltar para busca
Dado oficial do USPTO
IMMUNOSCAPE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
29/04/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
12/07/2018
Data de registro
28/04/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/04/2020
Última transação
29/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
2017-03-00
Primeiro uso no comércio
2017-03-00
Código do desenho
4
Tipo de titular
99
Localização do titular
Singapore, SG
Examinador
HETZEL, DANNEAN
Unidade examinadora
L60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
immunoscape Pte Ltd
Representantes
Jon Jekel Pillsbury Winthrop Shaw Pittman LLP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Research and development services in the field of biotechnology; Research and development services in the field of immune profiling; research and development services in the field of immunotherapy; biotechnology servicesprobing for multiple T cell specificities identification of tumor antigen-specific T cells for the treatment of cancer; biotechnology servicesprobing for multiple T cell specificities identification of viral antigen-specific T cells in the field of infectious diseases; biotechnology servicesphenotypic and functional T cell and/or other immune cells profiling for use in the field of immunotherapy; biotechnology servicesanalysis by time-of-flight mass cytometry; research services in the field of biomarker discovery; clinical research services for determining a response to treatment for patient stratification via biomarkersdetermining the presence of biomarkers in patient samples; biotechnology servicescharacterization of biomarkersdevelopment and evaluation of biochemicalbiological or analytical assays to quantify biomarkers and surrogate markers for the identification of patients and the treatment efficacy or prevention of diseasesdisorders and conditions associated with the immune system; consulting services in the field of biotechnology through the application of mass cytometry; Research and development services in the field of vaccines; research and development of immunotherapy products; research and development of vaccines for use in the field of immunotherapy; research and development services in the field of vaccinesimmunotherapies for the treatment of infectious diseases and cancer; biotechnology servicesanalysis by flow cytometry; consulting services in the field of vaccine research and development in the field of immunotherapies; platform as a service (PAAS) featuring computer software platforms for accessingcollectingdetectingcomparingcalculatinganalyzingdisplayingtransmittingmanaging and storing immune profiling data; providing temporary use of online non-downloadable computer software for use in performing lab servicesdescribing the status of disease progressionprioritization of treatment strategies; providing temporary use of online non-downloadable computer software for use in data collectionreviewinterpretationcomparisonanalysis of T cells and/or other immune cells features; providing temporary use of on-line non-downloadable cloud computing software for accessingcollectingdetectingcomparingcalculatinganalyzingdisplayingtransmittingmanaging and storing immune profiling data; providing temporary use of on-line non-downloadable cloud computing software for use in performing lab servicesdescribing the status of disease progressionprioritization of treatment strategies; providing temporary use of on-line non-downloadable cloud computing software for use in data collectionreviewinterpretationcomparisonanalysis of T cells and/or other immune cells features
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
03/09/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/09/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/09/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/09/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
28/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/02/2020
PUBO
PUBLISHED FOR OPPOSITION
11/02/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/01/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/01/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
30/12/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/12/2019
GNSL
LETTER OF SUSPENSION E-MAILED
05/12/2019
CNSL
SUSPENSION LETTER WRITTEN
05/12/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/12/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
22/11/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
20/11/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
20/11/2019
CNSI
SUSPENSION INQUIRY WRITTEN
20/11/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
19/11/2019
ALIE
ASSIGNED TO LIE
12/11/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
19/04/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
18/04/2019
GNSL
LETTER OF SUSPENSION E-MAILED
18/04/2019
CNSL
SUSPENSION LETTER WRITTEN
18/04/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/04/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/04/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/04/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/11/2018
GNRT
NON-FINAL ACTION E-MAILED
08/11/2018
CNRT
NON-FINAL ACTION WRITTEN
08/11/2018
DOCK
ASSIGNED TO EXAMINER
30/10/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/07/2018
NWAP
NEW APPLICATION ENTERED
16/07/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IMMUNOSCAPE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.